JTCS Concomitant Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

J Thorac Cardiovasc Surg 2008;135:578
© 2008 The American Association for Thoracic Surgery

Invited Commentary

Discussion

The first 20% of the full text of this article appears below.

Dr J. Conte (Baltimore, Md). The purpose of your study was to investigate whether aprotinin directly protects against glutamatergic excitotoxic injury. I think as far as your data are concerned, you've shown that very nicely. I think we can believe that.

I have 3 methodological questions, and I'd be remiss if I didn't go for the low-hanging fruit on this one as well.

The first has to do with the use of fetal tissue. Now, is there anything particular about fetal tissue in cell culture studies like this that would make it particularly amenable to the prevention of that type of injury and does it accurately reflect the type of glutamatergic-stimulated injury that . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The American Association for Thoracic Surgery.